Loading...

KALV KALVISTA PHARMACEUTICALS INC Capital Structure Changes 8-K Filing

KLVS

KLV

KALVISTA PHARMACEUTICALS INC

(KALV)

2025 8-K

Summary

Summary

New COO Appointment

Board Appointments

Convertible Notes Offering

Financial Results Revealed

Annual Meeting Update

Financial Statements

New Product Launches

License Agreement

Fiscal Year Change

Financial Results

Management Change

Financial Results

Board Appointment

Revenue Rights Sale

Annual Meeting Results

Management Changes

Financial Results

Lease Agreement

Financial Results

Financial Results

Public Offering

Termination of Sales Agreement

Clinical Data Announcement

Financial Results

Amendment to Certificate of...

Financial Results

Amended Employment Agreement

Financial Results

Appointment of President

External Links:

KalVista Pharmaceuticals, Inc. reported on September 24, 2025, that it sold $143.75 million in convertible senior notes with a 3.250% interest rate due in 2031. The company plans to use about $139 million in net proceeds for working capital and commercialization efforts for its product EKTERLY.

AI Assistant

KALVISTA PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.